nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—ACHE—prostate cancer	0.214	0.536	CbGaD
Mefloquine—CYP19A1—prostate cancer	0.126	0.316	CbGaD
Mefloquine—CYP3A4—prostate cancer	0.0592	0.148	CbGaD
Mefloquine—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0281	0.0948	CbGbCtD
Mefloquine—CYP2D6—Bicalutamide—prostate cancer	0.0232	0.0783	CbGbCtD
Mefloquine—ABCB1—Estramustine—prostate cancer	0.0229	0.0773	CbGbCtD
Mefloquine—CYP2D6—Abiraterone—prostate cancer	0.0192	0.0649	CbGbCtD
Mefloquine—ABCB1—Cabazitaxel—prostate cancer	0.0151	0.0509	CbGbCtD
Mefloquine—CYP3A4—Bicalutamide—prostate cancer	0.0147	0.0498	CbGbCtD
Mefloquine—ABCB1—Estrone—prostate cancer	0.0147	0.0498	CbGbCtD
Mefloquine—CYP3A4—Estramustine—prostate cancer	0.0137	0.0463	CbGbCtD
Mefloquine—ABCB1—Ethinyl Estradiol—prostate cancer	0.0131	0.0444	CbGbCtD
Mefloquine—CYP3A4—Flutamide—prostate cancer	0.0122	0.0413	CbGbCtD
Mefloquine—CYP3A4—Abiraterone—prostate cancer	0.0122	0.0413	CbGbCtD
Mefloquine—HBA1—urine—prostate cancer	0.0102	0.19	CbGeAlD
Mefloquine—ABCB1—Conjugated Estrogens—prostate cancer	0.00964	0.0326	CbGbCtD
Mefloquine—CYP3A4—Cabazitaxel—prostate cancer	0.00904	0.0305	CbGbCtD
Mefloquine—CYP3A4—Estrone—prostate cancer	0.00883	0.0298	CbGbCtD
Mefloquine—ABCB1—Mitoxantrone—prostate cancer	0.00877	0.0296	CbGbCtD
Mefloquine—ABCB1—Estradiol—prostate cancer	0.00847	0.0286	CbGbCtD
Mefloquine—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00787	0.0266	CbGbCtD
Mefloquine—ABCB1—Prednisone—prostate cancer	0.00728	0.0246	CbGbCtD
Mefloquine—CYP3A4—Conjugated Estrogens—prostate cancer	0.00578	0.0195	CbGbCtD
Mefloquine—ABCB1—Etoposide—prostate cancer	0.00553	0.0187	CbGbCtD
Mefloquine—CYP3A4—Mitoxantrone—prostate cancer	0.00525	0.0177	CbGbCtD
Mefloquine—CYP3A4—Estradiol—prostate cancer	0.00507	0.0171	CbGbCtD
Mefloquine—ABCB1—Docetaxel—prostate cancer	0.00506	0.0171	CbGbCtD
Mefloquine—CYP3A4—Prednisone—prostate cancer	0.00436	0.0147	CbGbCtD
Mefloquine—CYP19A1—semen—prostate cancer	0.00411	0.0761	CbGeAlD
Mefloquine—ABCB1—Doxorubicin—prostate cancer	0.00377	0.0127	CbGbCtD
Mefloquine—HBA1—prostate gland—prostate cancer	0.00368	0.0682	CbGeAlD
Mefloquine—CYP2D6—Doxorubicin—prostate cancer	0.00355	0.012	CbGbCtD
Mefloquine—HBA2—prostate gland—prostate cancer	0.00338	0.0626	CbGeAlD
Mefloquine—CYP3A4—Etoposide—prostate cancer	0.00331	0.0112	CbGbCtD
Mefloquine—CYP3A4—Docetaxel—prostate cancer	0.00303	0.0102	CbGbCtD
Mefloquine—HBA1—renal system—prostate cancer	0.00251	0.0465	CbGeAlD
Mefloquine—HBA2—epithelium—prostate cancer	0.00248	0.046	CbGeAlD
Mefloquine—HBA2—renal system—prostate cancer	0.0023	0.0427	CbGeAlD
Mefloquine—CYP3A4—Doxorubicin—prostate cancer	0.00226	0.00763	CbGbCtD
Mefloquine—HBA1—bone marrow—prostate cancer	0.0019	0.0351	CbGeAlD
Mefloquine—HBA2—bone marrow—prostate cancer	0.00174	0.0323	CbGeAlD
Mefloquine—HBA1—testis—prostate cancer	0.00162	0.03	CbGeAlD
Mefloquine—ACHE—prostate gland—prostate cancer	0.00151	0.028	CbGeAlD
Mefloquine—HBA2—testis—prostate cancer	0.00149	0.0276	CbGeAlD
Mefloquine—CYP3A4—urine—prostate cancer	0.00139	0.0258	CbGeAlD
Mefloquine—CYP2D6—urine—prostate cancer	0.00137	0.0254	CbGeAlD
Mefloquine—HBA1—lymph node—prostate cancer	0.00117	0.0218	CbGeAlD
Mefloquine—HBA2—lymph node—prostate cancer	0.00108	0.02	CbGeAlD
Mefloquine—ADORA1—renal system—prostate cancer	0.00103	0.0192	CbGeAlD
Mefloquine—CYP19A1—prostate gland—prostate cancer	0.00103	0.0191	CbGeAlD
Mefloquine—ADORA1—urethra—prostate cancer	0.00102	0.0188	CbGeAlD
Mefloquine—ADORA2A—testis—prostate cancer	0.000774	0.0144	CbGeAlD
Mefloquine—BCHE—prostate gland—prostate cancer	0.000741	0.0137	CbGeAlD
Mefloquine—ADORA1—testis—prostate cancer	0.000669	0.0124	CbGeAlD
Mefloquine—ACHE—testis—prostate cancer	0.000664	0.0123	CbGeAlD
Mefloquine—BCHE—seminal vesicle—prostate cancer	0.000627	0.0116	CbGeAlD
Mefloquine—ADORA1—lymph node—prostate cancer	0.000485	0.00898	CbGeAlD
Mefloquine—ACHE—lymph node—prostate cancer	0.000482	0.00893	CbGeAlD
Mefloquine—CYP19A1—testis—prostate cancer	0.000453	0.00841	CbGeAlD
Mefloquine—BCHE—bone marrow—prostate cancer	0.000382	0.00708	CbGeAlD
Mefloquine—ABCB1—prostate gland—prostate cancer	0.000353	0.00655	CbGeAlD
Mefloquine—CYP3A4—renal system—prostate cancer	0.00034	0.00631	CbGeAlD
Mefloquine—CYP2D6—renal system—prostate cancer	0.000335	0.00621	CbGeAlD
Mefloquine—CYP19A1—lymph node—prostate cancer	0.000329	0.00609	CbGeAlD
Mefloquine—BCHE—testis—prostate cancer	0.000327	0.00605	CbGeAlD
Mefloquine—ABCB1—seminal vesicle—prostate cancer	0.000299	0.00554	CbGeAlD
Mefloquine—ABCB1—epithelium—prostate cancer	0.00026	0.00481	CbGeAlD
Mefloquine—ABCB1—renal system—prostate cancer	0.000241	0.00446	CbGeAlD
Mefloquine—BCHE—lymph node—prostate cancer	0.000237	0.00439	CbGeAlD
Mefloquine—ABCB1—urethra—prostate cancer	0.000237	0.00439	CbGeAlD
Mefloquine—CYP2D6—testis—prostate cancer	0.000216	0.00401	CbGeAlD
Mefloquine—ABCB1—bone marrow—prostate cancer	0.000182	0.00338	CbGeAlD
Mefloquine—ABCB1—testis—prostate cancer	0.000156	0.00289	CbGeAlD
Mefloquine—ABCB1—lymph node—prostate cancer	0.000113	0.00209	CbGeAlD
Mefloquine—Renal failure—Doxorubicin—prostate cancer	4.71e-05	0.000338	CcSEcCtD
Mefloquine—Neuropathy peripheral—Doxorubicin—prostate cancer	4.69e-05	0.000337	CcSEcCtD
Mefloquine—Urticaria—Etoposide—prostate cancer	4.68e-05	0.000335	CcSEcCtD
Mefloquine—Malaise—Prednisone—prostate cancer	4.66e-05	0.000334	CcSEcCtD
Mefloquine—Shock—Capecitabine—prostate cancer	4.66e-05	0.000334	CcSEcCtD
Mefloquine—Abdominal pain—Etoposide—prostate cancer	4.66e-05	0.000334	CcSEcCtD
Mefloquine—Body temperature increased—Etoposide—prostate cancer	4.66e-05	0.000334	CcSEcCtD
Mefloquine—Nervous system disorder—Capecitabine—prostate cancer	4.65e-05	0.000333	CcSEcCtD
Mefloquine—Vertigo—Prednisone—prostate cancer	4.65e-05	0.000333	CcSEcCtD
Mefloquine—Thrombocytopenia—Capecitabine—prostate cancer	4.64e-05	0.000333	CcSEcCtD
Mefloquine—Syncope—Prednisone—prostate cancer	4.64e-05	0.000333	CcSEcCtD
Mefloquine—Tachycardia—Capecitabine—prostate cancer	4.62e-05	0.000332	CcSEcCtD
Mefloquine—Skin disorder—Capecitabine—prostate cancer	4.6e-05	0.00033	CcSEcCtD
Mefloquine—Sweating—Doxorubicin—prostate cancer	4.59e-05	0.000329	CcSEcCtD
Mefloquine—Hyperhidrosis—Capecitabine—prostate cancer	4.58e-05	0.000328	CcSEcCtD
Mefloquine—Hypotension—Docetaxel—prostate cancer	4.57e-05	0.000328	CcSEcCtD
Mefloquine—Connective tissue disorder—Epirubicin—prostate cancer	4.57e-05	0.000327	CcSEcCtD
Mefloquine—Loss of consciousness—Prednisone—prostate cancer	4.55e-05	0.000326	CcSEcCtD
Mefloquine—Hepatobiliary disease—Doxorubicin—prostate cancer	4.53e-05	0.000325	CcSEcCtD
Mefloquine—Nausea—Estradiol—prostate cancer	4.51e-05	0.000324	CcSEcCtD
Mefloquine—Vomiting—Mitoxantrone—prostate cancer	4.5e-05	0.000323	CcSEcCtD
Mefloquine—Convulsion—Prednisone—prostate cancer	4.48e-05	0.000321	CcSEcCtD
Mefloquine—Visual impairment—Epirubicin—prostate cancer	4.48e-05	0.000321	CcSEcCtD
Mefloquine—Agranulocytosis—Doxorubicin—prostate cancer	4.47e-05	0.00032	CcSEcCtD
Mefloquine—Hypertension—Prednisone—prostate cancer	4.47e-05	0.00032	CcSEcCtD
Mefloquine—Rash—Mitoxantrone—prostate cancer	4.46e-05	0.00032	CcSEcCtD
Mefloquine—Dermatitis—Mitoxantrone—prostate cancer	4.46e-05	0.00032	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Docetaxel—prostate cancer	4.46e-05	0.00032	CcSEcCtD
Mefloquine—Headache—Mitoxantrone—prostate cancer	4.44e-05	0.000318	CcSEcCtD
Mefloquine—Hypotension—Capecitabine—prostate cancer	4.43e-05	0.000318	CcSEcCtD
Mefloquine—Insomnia—Docetaxel—prostate cancer	4.43e-05	0.000317	CcSEcCtD
Mefloquine—Myalgia—Prednisone—prostate cancer	4.4e-05	0.000316	CcSEcCtD
Mefloquine—Arthralgia—Prednisone—prostate cancer	4.4e-05	0.000316	CcSEcCtD
Mefloquine—Paraesthesia—Docetaxel—prostate cancer	4.39e-05	0.000315	CcSEcCtD
Mefloquine—Erythema multiforme—Epirubicin—prostate cancer	4.39e-05	0.000315	CcSEcCtD
Mefloquine—Anxiety—Prednisone—prostate cancer	4.39e-05	0.000315	CcSEcCtD
Mefloquine—Bradycardia—Doxorubicin—prostate cancer	4.38e-05	0.000314	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	4.37e-05	0.000314	CcSEcCtD
Mefloquine—Dyspnoea—Docetaxel—prostate cancer	4.36e-05	0.000313	CcSEcCtD
Mefloquine—Somnolence—Docetaxel—prostate cancer	4.35e-05	0.000312	CcSEcCtD
Mefloquine—Discomfort—Prednisone—prostate cancer	4.35e-05	0.000312	CcSEcCtD
Mefloquine—Eye disorder—Epirubicin—prostate cancer	4.34e-05	0.000311	CcSEcCtD
Mefloquine—Hypersensitivity—Etoposide—prostate cancer	4.34e-05	0.000311	CcSEcCtD
Mefloquine—Tinnitus—Epirubicin—prostate cancer	4.33e-05	0.000311	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Capecitabine—prostate cancer	4.32e-05	0.00031	CcSEcCtD
Mefloquine—Cardiac disorder—Epirubicin—prostate cancer	4.31e-05	0.000309	CcSEcCtD
Mefloquine—Flushing—Epirubicin—prostate cancer	4.31e-05	0.000309	CcSEcCtD
Mefloquine—Dyspepsia—Docetaxel—prostate cancer	4.31e-05	0.000309	CcSEcCtD
Mefloquine—Insomnia—Capecitabine—prostate cancer	4.29e-05	0.000307	CcSEcCtD
Mefloquine—Paraesthesia—Capecitabine—prostate cancer	4.25e-05	0.000305	CcSEcCtD
Mefloquine—Decreased appetite—Docetaxel—prostate cancer	4.25e-05	0.000305	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Docetaxel—prostate cancer	4.23e-05	0.000303	CcSEcCtD
Mefloquine—Asthenia—Etoposide—prostate cancer	4.23e-05	0.000303	CcSEcCtD
Mefloquine—Connective tissue disorder—Doxorubicin—prostate cancer	4.22e-05	0.000303	CcSEcCtD
Mefloquine—Dyspnoea—Capecitabine—prostate cancer	4.22e-05	0.000303	CcSEcCtD
Mefloquine—Oedema—Prednisone—prostate cancer	4.22e-05	0.000303	CcSEcCtD
Mefloquine—Anaphylactic shock—Prednisone—prostate cancer	4.22e-05	0.000303	CcSEcCtD
Mefloquine—Fatigue—Docetaxel—prostate cancer	4.22e-05	0.000303	CcSEcCtD
Mefloquine—Angiopathy—Epirubicin—prostate cancer	4.22e-05	0.000302	CcSEcCtD
Mefloquine—Nausea—Mitoxantrone—prostate cancer	4.21e-05	0.000302	CcSEcCtD
Mefloquine—Mediastinal disorder—Epirubicin—prostate cancer	4.19e-05	0.0003	CcSEcCtD
Mefloquine—Dyspepsia—Capecitabine—prostate cancer	4.17e-05	0.000299	CcSEcCtD
Mefloquine—Chills—Epirubicin—prostate cancer	4.17e-05	0.000299	CcSEcCtD
Mefloquine—Pruritus—Etoposide—prostate cancer	4.17e-05	0.000299	CcSEcCtD
Mefloquine—Shock—Prednisone—prostate cancer	4.15e-05	0.000298	CcSEcCtD
Mefloquine—Visual impairment—Doxorubicin—prostate cancer	4.14e-05	0.000297	CcSEcCtD
Mefloquine—Nervous system disorder—Prednisone—prostate cancer	4.14e-05	0.000297	CcSEcCtD
Mefloquine—Tachycardia—Prednisone—prostate cancer	4.12e-05	0.000295	CcSEcCtD
Mefloquine—Decreased appetite—Capecitabine—prostate cancer	4.12e-05	0.000295	CcSEcCtD
Mefloquine—Alopecia—Epirubicin—prostate cancer	4.11e-05	0.000294	CcSEcCtD
Mefloquine—Skin disorder—Prednisone—prostate cancer	4.1e-05	0.000294	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Capecitabine—prostate cancer	4.09e-05	0.000293	CcSEcCtD
Mefloquine—Fatigue—Capecitabine—prostate cancer	4.09e-05	0.000293	CcSEcCtD
Mefloquine—Hyperhidrosis—Prednisone—prostate cancer	4.08e-05	0.000293	CcSEcCtD
Mefloquine—Mental disorder—Epirubicin—prostate cancer	4.07e-05	0.000292	CcSEcCtD
Mefloquine—Erythema multiforme—Doxorubicin—prostate cancer	4.06e-05	0.000292	CcSEcCtD
Mefloquine—Erythema—Epirubicin—prostate cancer	4.04e-05	0.00029	CcSEcCtD
Mefloquine—Malnutrition—Epirubicin—prostate cancer	4.04e-05	0.00029	CcSEcCtD
Mefloquine—Feeling abnormal—Docetaxel—prostate cancer	4.03e-05	0.000289	CcSEcCtD
Mefloquine—Diarrhoea—Etoposide—prostate cancer	4.03e-05	0.000289	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—prostate cancer	4.02e-05	0.000288	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—prostate cancer	4.01e-05	0.000287	CcSEcCtD
Mefloquine—Gastrointestinal pain—Docetaxel—prostate cancer	4e-05	0.000287	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—prostate cancer	3.99e-05	0.000286	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—prostate cancer	3.99e-05	0.000286	CcSEcCtD
Mefloquine—Feeling abnormal—Capecitabine—prostate cancer	3.9e-05	0.00028	CcSEcCtD
Mefloquine—Angiopathy—Doxorubicin—prostate cancer	3.9e-05	0.00028	CcSEcCtD
Mefloquine—Dizziness—Etoposide—prostate cancer	3.89e-05	0.000279	CcSEcCtD
Mefloquine—Muscle spasms—Epirubicin—prostate cancer	3.89e-05	0.000279	CcSEcCtD
Mefloquine—Gastrointestinal pain—Capecitabine—prostate cancer	3.87e-05	0.000278	CcSEcCtD
Mefloquine—Mediastinal disorder—Doxorubicin—prostate cancer	3.87e-05	0.000278	CcSEcCtD
Mefloquine—Abdominal pain—Docetaxel—prostate cancer	3.87e-05	0.000277	CcSEcCtD
Mefloquine—Body temperature increased—Docetaxel—prostate cancer	3.87e-05	0.000277	CcSEcCtD
Mefloquine—Chills—Doxorubicin—prostate cancer	3.86e-05	0.000277	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Prednisone—prostate cancer	3.85e-05	0.000276	CcSEcCtD
Mefloquine—Insomnia—Prednisone—prostate cancer	3.82e-05	0.000274	CcSEcCtD
Mefloquine—Vision blurred—Epirubicin—prostate cancer	3.81e-05	0.000273	CcSEcCtD
Mefloquine—Alopecia—Doxorubicin—prostate cancer	3.8e-05	0.000272	CcSEcCtD
Mefloquine—Paraesthesia—Prednisone—prostate cancer	3.79e-05	0.000272	CcSEcCtD
Mefloquine—Mental disorder—Doxorubicin—prostate cancer	3.77e-05	0.00027	CcSEcCtD
Mefloquine—Urticaria—Capecitabine—prostate cancer	3.76e-05	0.00027	CcSEcCtD
Mefloquine—Ill-defined disorder—Epirubicin—prostate cancer	3.75e-05	0.000269	CcSEcCtD
Mefloquine—Abdominal pain—Capecitabine—prostate cancer	3.75e-05	0.000269	CcSEcCtD
Mefloquine—Body temperature increased—Capecitabine—prostate cancer	3.75e-05	0.000269	CcSEcCtD
Mefloquine—Vomiting—Etoposide—prostate cancer	3.74e-05	0.000269	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—prostate cancer	3.74e-05	0.000268	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—prostate cancer	3.74e-05	0.000268	CcSEcCtD
Mefloquine—Agitation—Epirubicin—prostate cancer	3.72e-05	0.000267	CcSEcCtD
Mefloquine—Dyspepsia—Prednisone—prostate cancer	3.72e-05	0.000266	CcSEcCtD
Mefloquine—Rash—Etoposide—prostate cancer	3.71e-05	0.000266	CcSEcCtD
Mefloquine—Dermatitis—Etoposide—prostate cancer	3.71e-05	0.000266	CcSEcCtD
Mefloquine—Headache—Etoposide—prostate cancer	3.69e-05	0.000265	CcSEcCtD
Mefloquine—Decreased appetite—Prednisone—prostate cancer	3.67e-05	0.000263	CcSEcCtD
Mefloquine—Malaise—Epirubicin—prostate cancer	3.65e-05	0.000262	CcSEcCtD
Mefloquine—Fatigue—Prednisone—prostate cancer	3.64e-05	0.000261	CcSEcCtD
Mefloquine—Vertigo—Epirubicin—prostate cancer	3.63e-05	0.000261	CcSEcCtD
Mefloquine—Syncope—Epirubicin—prostate cancer	3.63e-05	0.00026	CcSEcCtD
Mefloquine—Leukopenia—Epirubicin—prostate cancer	3.62e-05	0.00026	CcSEcCtD
Mefloquine—Hypersensitivity—Docetaxel—prostate cancer	3.61e-05	0.000259	CcSEcCtD
Mefloquine—Muscle spasms—Doxorubicin—prostate cancer	3.6e-05	0.000258	CcSEcCtD
Mefloquine—Palpitations—Epirubicin—prostate cancer	3.57e-05	0.000256	CcSEcCtD
Mefloquine—Loss of consciousness—Epirubicin—prostate cancer	3.56e-05	0.000255	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—prostate cancer	3.53e-05	0.000253	CcSEcCtD
Mefloquine—Asthenia—Docetaxel—prostate cancer	3.51e-05	0.000252	CcSEcCtD
Mefloquine—Convulsion—Epirubicin—prostate cancer	3.5e-05	0.000251	CcSEcCtD
Mefloquine—Nausea—Etoposide—prostate cancer	3.5e-05	0.000251	CcSEcCtD
Mefloquine—Hypertension—Epirubicin—prostate cancer	3.49e-05	0.00025	CcSEcCtD
Mefloquine—Hypersensitivity—Capecitabine—prostate cancer	3.49e-05	0.00025	CcSEcCtD
Mefloquine—Feeling abnormal—Prednisone—prostate cancer	3.48e-05	0.000249	CcSEcCtD
Mefloquine—Ill-defined disorder—Doxorubicin—prostate cancer	3.47e-05	0.000249	CcSEcCtD
Mefloquine—Pruritus—Docetaxel—prostate cancer	3.46e-05	0.000248	CcSEcCtD
Mefloquine—Gastrointestinal pain—Prednisone—prostate cancer	3.45e-05	0.000248	CcSEcCtD
Mefloquine—Chest pain—Epirubicin—prostate cancer	3.44e-05	0.000247	CcSEcCtD
Mefloquine—Arthralgia—Epirubicin—prostate cancer	3.44e-05	0.000247	CcSEcCtD
Mefloquine—Myalgia—Epirubicin—prostate cancer	3.44e-05	0.000247	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—prostate cancer	3.44e-05	0.000247	CcSEcCtD
Mefloquine—Anxiety—Epirubicin—prostate cancer	3.43e-05	0.000246	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	3.42e-05	0.000245	CcSEcCtD
Mefloquine—Discomfort—Epirubicin—prostate cancer	3.4e-05	0.000244	CcSEcCtD
Mefloquine—Asthenia—Capecitabine—prostate cancer	3.4e-05	0.000244	CcSEcCtD
Mefloquine—Malaise—Doxorubicin—prostate cancer	3.38e-05	0.000242	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—prostate cancer	3.36e-05	0.000241	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—prostate cancer	3.36e-05	0.000241	CcSEcCtD
Mefloquine—Urticaria—Prednisone—prostate cancer	3.35e-05	0.00024	CcSEcCtD
Mefloquine—Pruritus—Capecitabine—prostate cancer	3.35e-05	0.00024	CcSEcCtD
Mefloquine—Leukopenia—Doxorubicin—prostate cancer	3.35e-05	0.00024	CcSEcCtD
Mefloquine—Diarrhoea—Docetaxel—prostate cancer	3.35e-05	0.00024	CcSEcCtD
Mefloquine—Abdominal pain—Prednisone—prostate cancer	3.34e-05	0.000239	CcSEcCtD
Mefloquine—Body temperature increased—Prednisone—prostate cancer	3.34e-05	0.000239	CcSEcCtD
Mefloquine—Confusional state—Epirubicin—prostate cancer	3.33e-05	0.000239	CcSEcCtD
Mefloquine—Palpitations—Doxorubicin—prostate cancer	3.31e-05	0.000237	CcSEcCtD
Mefloquine—Oedema—Epirubicin—prostate cancer	3.3e-05	0.000237	CcSEcCtD
Mefloquine—Anaphylactic shock—Epirubicin—prostate cancer	3.3e-05	0.000237	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—prostate cancer	3.29e-05	0.000236	CcSEcCtD
Mefloquine—Shock—Epirubicin—prostate cancer	3.25e-05	0.000233	CcSEcCtD
Mefloquine—Convulsion—Doxorubicin—prostate cancer	3.24e-05	0.000233	CcSEcCtD
Mefloquine—Diarrhoea—Capecitabine—prostate cancer	3.24e-05	0.000232	CcSEcCtD
Mefloquine—Nervous system disorder—Epirubicin—prostate cancer	3.24e-05	0.000232	CcSEcCtD
Mefloquine—Dizziness—Docetaxel—prostate cancer	3.24e-05	0.000232	CcSEcCtD
Mefloquine—Thrombocytopenia—Epirubicin—prostate cancer	3.23e-05	0.000232	CcSEcCtD
Mefloquine—Hypertension—Doxorubicin—prostate cancer	3.23e-05	0.000232	CcSEcCtD
Mefloquine—Tachycardia—Epirubicin—prostate cancer	3.22e-05	0.000231	CcSEcCtD
Mefloquine—Skin disorder—Epirubicin—prostate cancer	3.21e-05	0.00023	CcSEcCtD
Mefloquine—Hyperhidrosis—Epirubicin—prostate cancer	3.19e-05	0.000229	CcSEcCtD
Mefloquine—Chest pain—Doxorubicin—prostate cancer	3.19e-05	0.000228	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—prostate cancer	3.19e-05	0.000228	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—prostate cancer	3.19e-05	0.000228	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—prostate cancer	3.18e-05	0.000228	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	3.16e-05	0.000227	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—prostate cancer	3.15e-05	0.000226	CcSEcCtD
Mefloquine—Dizziness—Capecitabine—prostate cancer	3.13e-05	0.000225	CcSEcCtD
Mefloquine—Vomiting—Docetaxel—prostate cancer	3.11e-05	0.000223	CcSEcCtD
Mefloquine—Hypersensitivity—Prednisone—prostate cancer	3.11e-05	0.000223	CcSEcCtD
Mefloquine—Rash—Docetaxel—prostate cancer	3.09e-05	0.000221	CcSEcCtD
Mefloquine—Hypotension—Epirubicin—prostate cancer	3.08e-05	0.000221	CcSEcCtD
Mefloquine—Dermatitis—Docetaxel—prostate cancer	3.08e-05	0.000221	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—prostate cancer	3.08e-05	0.000221	CcSEcCtD
Mefloquine—Headache—Docetaxel—prostate cancer	3.07e-05	0.00022	CcSEcCtD
Mefloquine—Anaphylactic shock—Doxorubicin—prostate cancer	3.05e-05	0.000219	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—prostate cancer	3.05e-05	0.000219	CcSEcCtD
Mefloquine—Asthenia—Prednisone—prostate cancer	3.03e-05	0.000217	CcSEcCtD
Mefloquine—Vomiting—Capecitabine—prostate cancer	3.01e-05	0.000216	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Epirubicin—prostate cancer	3.01e-05	0.000216	CcSEcCtD
Mefloquine—Shock—Doxorubicin—prostate cancer	3.01e-05	0.000215	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—prostate cancer	3e-05	0.000215	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—prostate cancer	2.99e-05	0.000214	CcSEcCtD
Mefloquine—Rash—Capecitabine—prostate cancer	2.99e-05	0.000214	CcSEcCtD
Mefloquine—Pruritus—Prednisone—prostate cancer	2.99e-05	0.000214	CcSEcCtD
Mefloquine—Insomnia—Epirubicin—prostate cancer	2.99e-05	0.000214	CcSEcCtD
Mefloquine—Dermatitis—Capecitabine—prostate cancer	2.98e-05	0.000214	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—prostate cancer	2.98e-05	0.000214	CcSEcCtD
Mefloquine—Headache—Capecitabine—prostate cancer	2.97e-05	0.000213	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—prostate cancer	2.97e-05	0.000213	CcSEcCtD
Mefloquine—Paraesthesia—Epirubicin—prostate cancer	2.96e-05	0.000213	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—prostate cancer	2.95e-05	0.000212	CcSEcCtD
Mefloquine—Dyspnoea—Epirubicin—prostate cancer	2.94e-05	0.000211	CcSEcCtD
Mefloquine—Somnolence—Epirubicin—prostate cancer	2.93e-05	0.00021	CcSEcCtD
Mefloquine—Nausea—Docetaxel—prostate cancer	2.91e-05	0.000208	CcSEcCtD
Mefloquine—Dyspepsia—Epirubicin—prostate cancer	2.91e-05	0.000208	CcSEcCtD
Mefloquine—Diarrhoea—Prednisone—prostate cancer	2.89e-05	0.000207	CcSEcCtD
Mefloquine—Decreased appetite—Epirubicin—prostate cancer	2.87e-05	0.000206	CcSEcCtD
Mefloquine—Hypotension—Doxorubicin—prostate cancer	2.85e-05	0.000205	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Epirubicin—prostate cancer	2.85e-05	0.000204	CcSEcCtD
Mefloquine—Fatigue—Epirubicin—prostate cancer	2.85e-05	0.000204	CcSEcCtD
Mefloquine—Nausea—Capecitabine—prostate cancer	2.81e-05	0.000202	CcSEcCtD
Mefloquine—Dizziness—Prednisone—prostate cancer	2.79e-05	0.0002	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.78e-05	0.0002	CcSEcCtD
Mefloquine—Insomnia—Doxorubicin—prostate cancer	2.76e-05	0.000198	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—prostate cancer	2.74e-05	0.000197	CcSEcCtD
Mefloquine—Dyspnoea—Doxorubicin—prostate cancer	2.72e-05	0.000195	CcSEcCtD
Mefloquine—Feeling abnormal—Epirubicin—prostate cancer	2.72e-05	0.000195	CcSEcCtD
Mefloquine—Somnolence—Doxorubicin—prostate cancer	2.72e-05	0.000195	CcSEcCtD
Mefloquine—Gastrointestinal pain—Epirubicin—prostate cancer	2.7e-05	0.000194	CcSEcCtD
Mefloquine—Dyspepsia—Doxorubicin—prostate cancer	2.69e-05	0.000193	CcSEcCtD
Mefloquine—Vomiting—Prednisone—prostate cancer	2.68e-05	0.000192	CcSEcCtD
Mefloquine—Rash—Prednisone—prostate cancer	2.66e-05	0.000191	CcSEcCtD
Mefloquine—Dermatitis—Prednisone—prostate cancer	2.66e-05	0.000191	CcSEcCtD
Mefloquine—Decreased appetite—Doxorubicin—prostate cancer	2.66e-05	0.00019	CcSEcCtD
Mefloquine—Headache—Prednisone—prostate cancer	2.64e-05	0.00019	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—prostate cancer	2.64e-05	0.000189	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—prostate cancer	2.63e-05	0.000189	CcSEcCtD
Mefloquine—Urticaria—Epirubicin—prostate cancer	2.62e-05	0.000188	CcSEcCtD
Mefloquine—Abdominal pain—Epirubicin—prostate cancer	2.61e-05	0.000187	CcSEcCtD
Mefloquine—Body temperature increased—Epirubicin—prostate cancer	2.61e-05	0.000187	CcSEcCtD
Mefloquine—Feeling abnormal—Doxorubicin—prostate cancer	2.52e-05	0.00018	CcSEcCtD
Mefloquine—Nausea—Prednisone—prostate cancer	2.51e-05	0.00018	CcSEcCtD
Mefloquine—Gastrointestinal pain—Doxorubicin—prostate cancer	2.5e-05	0.000179	CcSEcCtD
Mefloquine—Hypersensitivity—Epirubicin—prostate cancer	2.43e-05	0.000174	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—prostate cancer	2.43e-05	0.000174	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—prostate cancer	2.41e-05	0.000173	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—prostate cancer	2.41e-05	0.000173	CcSEcCtD
Mefloquine—Asthenia—Epirubicin—prostate cancer	2.37e-05	0.00017	CcSEcCtD
Mefloquine—Pruritus—Epirubicin—prostate cancer	2.34e-05	0.000167	CcSEcCtD
Mefloquine—Diarrhoea—Epirubicin—prostate cancer	2.26e-05	0.000162	CcSEcCtD
Mefloquine—Hypersensitivity—Doxorubicin—prostate cancer	2.25e-05	0.000161	CcSEcCtD
Mefloquine—Asthenia—Doxorubicin—prostate cancer	2.19e-05	0.000157	CcSEcCtD
Mefloquine—Dizziness—Epirubicin—prostate cancer	2.18e-05	0.000157	CcSEcCtD
Mefloquine—Pruritus—Doxorubicin—prostate cancer	2.16e-05	0.000155	CcSEcCtD
Mefloquine—Vomiting—Epirubicin—prostate cancer	2.1e-05	0.000151	CcSEcCtD
Mefloquine—Diarrhoea—Doxorubicin—prostate cancer	2.09e-05	0.00015	CcSEcCtD
Mefloquine—Rash—Epirubicin—prostate cancer	2.08e-05	0.000149	CcSEcCtD
Mefloquine—Dermatitis—Epirubicin—prostate cancer	2.08e-05	0.000149	CcSEcCtD
Mefloquine—Headache—Epirubicin—prostate cancer	2.07e-05	0.000148	CcSEcCtD
Mefloquine—Dizziness—Doxorubicin—prostate cancer	2.02e-05	0.000145	CcSEcCtD
Mefloquine—Nausea—Epirubicin—prostate cancer	1.96e-05	0.000141	CcSEcCtD
Mefloquine—Vomiting—Doxorubicin—prostate cancer	1.94e-05	0.000139	CcSEcCtD
Mefloquine—Rash—Doxorubicin—prostate cancer	1.93e-05	0.000138	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—prostate cancer	1.92e-05	0.000138	CcSEcCtD
Mefloquine—Headache—Doxorubicin—prostate cancer	1.91e-05	0.000137	CcSEcCtD
Mefloquine—Nausea—Doxorubicin—prostate cancer	1.81e-05	0.00013	CcSEcCtD
Mefloquine—CYP3A4—Metabolism—ACSL4—prostate cancer	3.28e-06	2.94e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HSD17B3—prostate cancer	3.28e-06	2.94e-05	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—AKT1—prostate cancer	3.28e-06	2.94e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.28e-06	2.93e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IGF1—prostate cancer	3.26e-06	2.92e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CASP3—prostate cancer	3.25e-06	2.91e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL2—prostate cancer	3.25e-06	2.91e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—EGFR—prostate cancer	3.24e-06	2.9e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL6—prostate cancer	3.23e-06	2.89e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—HPGDS—prostate cancer	3.23e-06	2.89e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—INS—prostate cancer	3.22e-06	2.88e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP2C19—prostate cancer	3.21e-06	2.87e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NCOA3—prostate cancer	3.19e-06	2.85e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.18e-06	2.85e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCND1—prostate cancer	3.16e-06	2.83e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CREBBP—prostate cancer	3.15e-06	2.82e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAP2K1—prostate cancer	3.15e-06	2.82e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PHGDH—prostate cancer	3.15e-06	2.82e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—UMPS—prostate cancer	3.15e-06	2.82e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ARG2—prostate cancer	3.15e-06	2.82e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CTNNB1—prostate cancer	3.13e-06	2.8e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CD—prostate cancer	3.13e-06	2.8e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTT1—prostate cancer	3.13e-06	2.8e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ACHE—prostate cancer	3.13e-06	2.8e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CG—prostate cancer	3.13e-06	2.8e-05	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—PIK3CA—prostate cancer	3.1e-06	2.78e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SERPINE1—prostate cancer	3.1e-06	2.77e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP2A6—prostate cancer	3.09e-06	2.77e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—LDHB—prostate cancer	3.09e-06	2.76e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MMP9—prostate cancer	3.07e-06	2.75e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—KRAS—prostate cancer	3.07e-06	2.74e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDKN1A—prostate cancer	3.06e-06	2.74e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PTEN—prostate cancer	3.05e-06	2.73e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—HPGDS—prostate cancer	3.04e-06	2.72e-05	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—prostate cancer	3.04e-06	2.72e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CG—prostate cancer	3.03e-06	2.72e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP3A5—prostate cancer	3.03e-06	2.71e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP2C19—prostate cancer	3.02e-06	2.71e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—AKR1C3—prostate cancer	3.01e-06	2.69e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FGF2—prostate cancer	3e-06	2.68e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PRKACB—prostate cancer	2.99e-06	2.68e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CD—prostate cancer	2.99e-06	2.68e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—AKT1—prostate cancer	2.98e-06	2.67e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP17A1—prostate cancer	2.96e-06	2.65e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—INS—prostate cancer	2.96e-06	2.65e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NOS3—prostate cancer	2.96e-06	2.65e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTT1—prostate cancer	2.95e-06	2.64e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ACHE—prostate cancer	2.95e-06	2.64e-05	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—CREBBP—prostate cancer	2.93e-06	2.62e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—UCP3—prostate cancer	2.93e-06	2.62e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PDHA1—prostate cancer	2.93e-06	2.62e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TCN2—prostate cancer	2.93e-06	2.62e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTA3—prostate cancer	2.93e-06	2.62e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP2A6—prostate cancer	2.92e-06	2.61e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EP300—prostate cancer	2.91e-06	2.61e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CREBBP—prostate cancer	2.9e-06	2.59e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—JAK2—prostate cancer	2.87e-06	2.57e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—INS—prostate cancer	2.87e-06	2.57e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AKR1C3—prostate cancer	2.84e-06	2.54e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SRC—prostate cancer	2.83e-06	2.54e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NCOA2—prostate cancer	2.82e-06	2.53e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—NOS3—prostate cancer	2.82e-06	2.53e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PRKACB—prostate cancer	2.82e-06	2.53e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PIK3CA—prostate cancer	2.82e-06	2.52e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CREBBP—prostate cancer	2.81e-06	2.52e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MDM2—prostate cancer	2.8e-06	2.51e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP17A1—prostate cancer	2.79e-06	2.5e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HSD3B1—prostate cancer	2.79e-06	2.5e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC22A3—prostate cancer	2.79e-06	2.5e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ERBB2—prostate cancer	2.77e-06	2.48e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—VEGFA—prostate cancer	2.76e-06	2.47e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CD—prostate cancer	2.75e-06	2.46e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—STAT3—prostate cancer	2.73e-06	2.44e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CB—prostate cancer	2.73e-06	2.44e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC5A5—prostate cancer	2.69e-06	2.41e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTA4—prostate cancer	2.68e-06	2.4e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TBXAS1—prostate cancer	2.68e-06	2.4e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CD—prostate cancer	2.67e-06	2.39e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NCOA2—prostate cancer	2.66e-06	2.38e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP2E1—prostate cancer	2.63e-06	2.36e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CXCL8—prostate cancer	2.62e-06	2.35e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTA2—prostate cancer	2.61e-06	2.33e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CB—prostate cancer	2.61e-06	2.33e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NQO1—prostate cancer	2.6e-06	2.33e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—NOS3—prostate cancer	2.59e-06	2.32e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTGS2—prostate cancer	2.58e-06	2.31e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SULT1A1—prostate cancer	2.58e-06	2.31e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCG5—prostate cancer	2.58e-06	2.31e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—TH—prostate cancer	2.56e-06	2.3e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN1B—prostate cancer	2.56e-06	2.29e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC5A5—prostate cancer	2.54e-06	2.27e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MYC—prostate cancer	2.54e-06	2.27e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP3A4—prostate cancer	2.54e-06	2.27e-05	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—AKT1—prostate cancer	2.53e-06	2.27e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TGFB1—prostate cancer	2.53e-06	2.27e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—NOS3—prostate cancer	2.52e-06	2.26e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTA1—prostate cancer	2.52e-06	2.25e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CASP3—prostate cancer	2.51e-06	2.25e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL2—prostate cancer	2.51e-06	2.24e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP1B1—prostate cancer	2.49e-06	2.23e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL6—prostate cancer	2.49e-06	2.23e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HSD3B2—prostate cancer	2.49e-06	2.23e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NAT2—prostate cancer	2.49e-06	2.23e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTO1—prostate cancer	2.49e-06	2.23e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EGFR—prostate cancer	2.48e-06	2.22e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP2E1—prostate cancer	2.48e-06	2.22e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NQO1—prostate cancer	2.45e-06	2.19e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCND1—prostate cancer	2.44e-06	2.19e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CTNNB1—prostate cancer	2.42e-06	2.17e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—TH—prostate cancer	2.42e-06	2.16e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GGT1—prostate cancer	2.42e-06	2.16e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CB—prostate cancer	2.4e-06	2.14e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP3A4—prostate cancer	2.39e-06	2.14e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—LRP2—prostate cancer	2.38e-06	2.13e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PLCB2—prostate cancer	2.38e-06	2.13e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP2C18—prostate cancer	2.38e-06	2.13e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NCOA1—prostate cancer	2.38e-06	2.13e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTGS2—prostate cancer	2.37e-06	2.12e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MMP9—prostate cancer	2.37e-06	2.12e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN1A—prostate cancer	2.36e-06	2.12e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTEN—prostate cancer	2.36e-06	2.11e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP1B1—prostate cancer	2.35e-06	2.1e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP19A1—prostate cancer	2.35e-06	2.1e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KRAS—prostate cancer	2.35e-06	2.1e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—P4HB—prostate cancer	2.34e-06	2.09e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CB—prostate cancer	2.33e-06	2.08e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTGS2—prostate cancer	2.3e-06	2.06e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—AKT1—prostate cancer	2.3e-06	2.06e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GGT1—prostate cancer	2.28e-06	2.04e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC22A1—prostate cancer	2.28e-06	2.04e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—RXRA—prostate cancer	2.26e-06	2.03e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTEN—prostate cancer	2.25e-06	2.02e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EP300—prostate cancer	2.25e-06	2.01e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NCOA1—prostate cancer	2.24e-06	2.01e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SULT2A1—prostate cancer	2.22e-06	1.98e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP19A1—prostate cancer	2.21e-06	1.98e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SRC—prostate cancer	2.19e-06	1.96e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MED12—prostate cancer	2.18e-06	1.95e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—COMT—prostate cancer	2.18e-06	1.95e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTP1—prostate cancer	2.17e-06	1.94e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GNG5—prostate cancer	2.16e-06	1.94e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CA—prostate cancer	2.15e-06	1.93e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—EP300—prostate cancer	2.15e-06	1.92e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ITPR1—prostate cancer	2.14e-06	1.91e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—RXRA—prostate cancer	2.13e-06	1.91e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—VEGFA—prostate cancer	2.13e-06	1.91e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—STAT3—prostate cancer	2.11e-06	1.89e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NCOA3—prostate cancer	2.08e-06	1.87e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—prostate cancer	2.08e-06	1.87e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTEN—prostate cancer	2.07e-06	1.85e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—COMT—prostate cancer	2.05e-06	1.84e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTP1—prostate cancer	2.04e-06	1.83e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—TYMS—prostate cancer	2.02e-06	1.81e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ITPR1—prostate cancer	2.01e-06	1.8e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTEN—prostate cancer	2.01e-06	1.8e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTM1—prostate cancer	1.99e-06	1.78e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HPGDS—prostate cancer	1.99e-06	1.78e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP2C19—prostate cancer	1.98e-06	1.77e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—EP300—prostate cancer	1.97e-06	1.77e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MYC—prostate cancer	1.96e-06	1.75e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—LPL—prostate cancer	1.96e-06	1.75e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TGFB1—prostate cancer	1.95e-06	1.75e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTT1—prostate cancer	1.93e-06	1.73e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ACHE—prostate cancer	1.93e-06	1.73e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EGFR—prostate cancer	1.92e-06	1.72e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—EP300—prostate cancer	1.92e-06	1.72e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL6—prostate cancer	1.91e-06	1.71e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP2A6—prostate cancer	1.91e-06	1.71e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—TYMS—prostate cancer	1.9e-06	1.7e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYP1A1—prostate cancer	1.89e-06	1.69e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTM1—prostate cancer	1.88e-06	1.68e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ERCC2—prostate cancer	1.87e-06	1.68e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AKR1C3—prostate cancer	1.85e-06	1.66e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PRKACB—prostate cancer	1.84e-06	1.65e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—LPL—prostate cancer	1.84e-06	1.65e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP17A1—prostate cancer	1.83e-06	1.63e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KRAS—prostate cancer	1.81e-06	1.62e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYP1A1—prostate cancer	1.78e-06	1.59e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ERCC2—prostate cancer	1.77e-06	1.58e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—MTHFR—prostate cancer	1.76e-06	1.58e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—AKT1—prostate cancer	1.76e-06	1.58e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NCOA2—prostate cancer	1.74e-06	1.56e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PPARA—prostate cancer	1.73e-06	1.55e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CA—prostate cancer	1.66e-06	1.49e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—MTHFR—prostate cancer	1.66e-06	1.49e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC5A5—prostate cancer	1.66e-06	1.49e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PPARA—prostate cancer	1.63e-06	1.46e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CAV1—prostate cancer	1.63e-06	1.46e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP2E1—prostate cancer	1.62e-06	1.45e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—prostate cancer	1.61e-06	1.44e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NQO1—prostate cancer	1.6e-06	1.43e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CA—prostate cancer	1.59e-06	1.42e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TH—prostate cancer	1.58e-06	1.41e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.54e-06	1.38e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CAV1—prostate cancer	1.53e-06	1.37e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GGT1—prostate cancer	1.49e-06	1.33e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CG—prostate cancer	1.48e-06	1.33e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL6—prostate cancer	1.47e-06	1.32e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NCOA1—prostate cancer	1.47e-06	1.31e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CA—prostate cancer	1.46e-06	1.31e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.44e-06	1.29e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CA—prostate cancer	1.42e-06	1.27e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—INS—prostate cancer	1.4e-06	1.25e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.4e-06	1.25e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—RXRA—prostate cancer	1.39e-06	1.25e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CREBBP—prostate cancer	1.37e-06	1.23e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—AKT1—prostate cancer	1.36e-06	1.22e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—COMT—prostate cancer	1.34e-06	1.2e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTP1—prostate cancer	1.34e-06	1.2e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—INS—prostate cancer	1.32e-06	1.18e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ITPR1—prostate cancer	1.32e-06	1.18e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CD—prostate cancer	1.3e-06	1.17e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—AKT1—prostate cancer	1.3e-06	1.16e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CREBBP—prostate cancer	1.29e-06	1.16e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TYMS—prostate cancer	1.24e-06	1.11e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NOS3—prostate cancer	1.23e-06	1.1e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTM1—prostate cancer	1.23e-06	1.1e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.23e-06	1.1e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—LPL—prostate cancer	1.21e-06	1.08e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—AKT1—prostate cancer	1.19e-06	1.07e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.16e-06	1.04e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NOS3—prostate cancer	1.16e-06	1.04e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—AKT1—prostate cancer	1.16e-06	1.04e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ERCC2—prostate cancer	1.16e-06	1.03e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CB—prostate cancer	1.13e-06	1.02e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTGS2—prostate cancer	1.12e-06	1.01e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MTHFR—prostate cancer	1.09e-06	9.72e-06	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.07e-06	9.57e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PPARA—prostate cancer	1.07e-06	9.54e-06	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTGS2—prostate cancer	1.06e-06	9.48e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CAV1—prostate cancer	1e-06	8.97e-06	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTEN—prostate cancer	9.8e-07	8.78e-06	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—EP300—prostate cancer	9.35e-07	8.37e-06	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTEN—prostate cancer	9.24e-07	8.27e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CG—prostate cancer	9.12e-07	8.17e-06	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—EP300—prostate cancer	8.81e-07	7.89e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—INS—prostate cancer	8.64e-07	7.73e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CREBBP—prostate cancer	8.46e-07	7.57e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CD—prostate cancer	8.02e-07	7.18e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NOS3—prostate cancer	7.57e-07	6.78e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CB—prostate cancer	6.99e-07	6.26e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTGS2—prostate cancer	6.93e-07	6.2e-06	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CA—prostate cancer	6.92e-07	6.19e-06	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CA—prostate cancer	6.52e-07	5.83e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTEN—prostate cancer	6.04e-07	5.41e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—EP300—prostate cancer	5.76e-07	5.16e-06	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—AKT1—prostate cancer	5.65e-07	5.06e-06	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AKT1—prostate cancer	5.32e-07	4.77e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CA—prostate cancer	4.26e-07	3.81e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AKT1—prostate cancer	3.48e-07	3.12e-06	CbGpPWpGaD
